Search research articles
Contact Us
Filters
Showing results (11-20 of 43) with videos related to
Page
of 5
Sort By:
Journal of Clinical Pharmacology
|
December 28, 2020
Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma
Neang Ly, Yanan Zheng, Janet M Griffiths, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 6, 2021
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy
Jonathan Corren, Christopher S Ambrose, Kinga Sałapa, et al.
Journal of the American Academy of Dermatology
|
December 15, 2018
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial
Eric L Simpson, Jane R Parnes, Dewei She, et al.
The New England Journal of Medicine
|
September 7, 2017
Tezepelumab in Adults with Uncontrolled Asthma
Jonathan Corren, Jane R Parnes, Liangwei Wang, et al.
Clinical Pharmacology and Therapeutics
|
May 8, 2023
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials
Lubna Abuqayyas, Po-Wei Chen, Marcia Teixeira Dos Santos, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
November 10, 2020
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY
Jonathan Corren, Esther Garcia Gil, Janet M Griffiths, et al.
Allergy
|
December 16, 2021
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma
Jonathan Corren, Tuyet-Hang Pham, Esther Garcia Gil, et al.
Respiratory Research
|
October 14, 2020
CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
Claire Emson, Sarah Diver, Latifa Chachi, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 20, 2006
CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes
Daniel H Li, James W Tung, Ingo H Tarner, et al.
Nature Immunology
|
May 23, 2006
Medicine on a need-to-know basis
Robert Busch, Belinda Byrne, Laurie Gandrud, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 43) with videos related to
Sort By:
Page
of 5
Journal of Clinical Pharmacology
|
December 28, 2020
Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma
Neang Ly, Yanan Zheng, Janet M Griffiths, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
August 6, 2021
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy
Jonathan Corren, Christopher S Ambrose, Kinga Sałapa, et al.
Journal of the American Academy of Dermatology
|
December 15, 2018
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial
Eric L Simpson, Jane R Parnes, Dewei She, et al.
The New England Journal of Medicine
|
September 7, 2017
Tezepelumab in Adults with Uncontrolled Asthma
Jonathan Corren, Jane R Parnes, Liangwei Wang, et al.
Clinical Pharmacology and Therapeutics
|
May 8, 2023
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials
Lubna Abuqayyas, Po-Wei Chen, Marcia Teixeira Dos Santos, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|
November 10, 2020
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY
Jonathan Corren, Esther Garcia Gil, Janet M Griffiths, et al.
Allergy
|
December 16, 2021
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma
Jonathan Corren, Tuyet-Hang Pham, Esther Garcia Gil, et al.
Respiratory Research
|
October 14, 2020
CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma
Claire Emson, Sarah Diver, Latifa Chachi, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
April 20, 2006
CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes
Daniel H Li, James W Tung, Ingo H Tarner, et al.
Nature Immunology
|
May 23, 2006
Medicine on a need-to-know basis
Robert Busch, Belinda Byrne, Laurie Gandrud, et al.
Page
of 5